Mexico is one of the three countries in Region of Americas with the highest prevalence (14.4%) of DM. We conducted a retrospective study in Mexico and compare Dapagliflozin effect in cardio-renal outcomes and metabolic control compared to DPP4-inhibitors (DPP4i) as added-on therapy in T2DM patients with failure to previous medications.

Objectives: Compare proportion of patients achieving HbA1c below 7%, first appearance of eGFR below 60 ml/min, renal replacement therapy, heart failure hospitalization and death by the end of the 156-week observation period from index date.

Inclusion Criteria: T2DM subjects ≥18 years old with failure to any previous antidiabetic medication and HbA1c% ≥7 that started Dapa or DPP4i as add-on to other antidiabetic drugs from August 2014 to December 2019.

Statistical Methods and Analysis: A propensity score matching model (nearest neighbor algorithm) was used.

Results: Of 1800 subjects, 267 met statistical matching criteria. There were no differences in basal characteristics of age, SBP, Creatinine Clearance, but DAPA group had higher basal HbA1c (8.54±1.45 vs 8.16±1.43, p<0.01). Patients in Dapa compared to DPP4i achieved A1c ≤7% in 49.8% vs 20% (p<0.01) by week 156. Creatinine clearance between groups favored DAPA after week 52 (76.07±18.52 vs 86.40±21.27, p<0.01), and persisted through week 156 (68.19±19.4 vs 88.45±19.73, p<0.01). By week 52, Incidental CKD was present in 5.8% of Dapa group and in 14.8% of DPP4i group, p=0.013 (OR 0.607, 95% IC 0.409-0.901), and by week 156 6.5% DAPA vs 27.6% DPP4i, p<0.01 (OR 0.275, 95% IC 0.191-396). There were no differences in HF hospitalizations.

Conclusion: In patients with uncontrolled T2DM who have failed to previous antidiabetic therapies, the add-on of dapagliflozin significantly provides reductions of HbA1c, microalbuminuria and reduces the risk of CKD compared to DPP4i add-on.

Disclosure

D.Espinoza-peralta: None. S.C.Juarez-comboni: Employee; AstraZeneca. A.M.Rodríguez: Employee; AstraZeneca. J.Hernandez-alarcon: None. I.N.Lopez: None. J.Cetina-canto: None. M.E.Búrquez-gonzález: None. P.V.Paul: None. G.A.Bustamante: None. J.Garnica cuellar: None. L.G.Mireles-zavala: None.

© 2023 by the American Diabetes Association
2023
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.